




FIG. 1




FIG. 2




FIG. 3

Inhibition of CD39 enzyme activity in hCD39-HEK293T




FIG. 4

Inhibition of CD39 enzyme activity in PBMC cells




FIG. 5

Inhibition of soluble CD39 (0.5 μ g mL) enzyme activity




FIG. 6

Binding activity to CHO-hCD39 cells




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14

Reversing CD4-T cell proliferation inhibition mediated by ATP hydrolysis (day 3)




FIG. 15

Reversing CD8-T cell proliferation inhibition mediated by ATP hydrolysis (day 3)




FIG. 16




FIG. 17

Inhibition of CD39 enzyme activity in hCD39-HEK293T




FIG. 18

Inhibition of soluble CD39 (2µg mL) enzyme activity




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25

Inhibition of soluble CD39 (1µg/mL) enzyme activity




FIG. 26

Inhibition of CD39 enzyme activity in PBMC cells




FIG. 27

Reversing cell proliferation inhibition




FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36




FIG. 37




FIG. 38




FIG. 39